JP2018500332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500332A5 JP2018500332A5 JP2017532140A JP2017532140A JP2018500332A5 JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5 JP 2017532140 A JP2017532140 A JP 2017532140A JP 2017532140 A JP2017532140 A JP 2017532140A JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- dose
- ctla
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 5
- 206010018338 Glioma Diseases 0.000 claims 5
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010073338 Optic glioma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000008511 optic nerve glioma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131637A JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092783P | 2014-12-16 | 2014-12-16 | |
| US62/092,783 | 2014-12-16 | ||
| US201562261130P | 2015-11-30 | 2015-11-30 | |
| US62/261,130 | 2015-11-30 | ||
| PCT/US2015/066177 WO2016100561A2 (en) | 2014-12-16 | 2015-12-16 | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131637A Division JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500332A JP2018500332A (ja) | 2018-01-11 |
| JP2018500332A5 true JP2018500332A5 (enExample) | 2019-01-31 |
Family
ID=56127849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532140A Pending JP2018500332A (ja) | 2014-12-16 | 2015-12-16 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
| JP2021131637A Pending JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131637A Pending JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180133313A1 (enExample) |
| EP (1) | EP3233123A4 (enExample) |
| JP (2) | JP2018500332A (enExample) |
| CN (1) | CN106999590A (enExample) |
| BR (1) | BR112017010101A2 (enExample) |
| CA (1) | CA2969338A1 (enExample) |
| MX (1) | MX2017007390A (enExample) |
| RU (1) | RU2726996C1 (enExample) |
| WO (1) | WO2016100561A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
| EP3497129A1 (en) * | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
| WO2018106729A1 (en) * | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| DE102017119868B4 (de) * | 2017-07-12 | 2021-05-27 | Bruker Daltonik Gmbh | Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie |
| US10617667B2 (en) * | 2017-11-01 | 2020-04-14 | Ono Pharmaceutical Co., Ltd. | Method for treating brain tumors |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CN112203688A (zh) * | 2018-05-31 | 2021-01-08 | 小野药品工业株式会社 | 用于确定免疫检查点抑制剂的有效性的生物标志物 |
| EP3941467A4 (en) * | 2019-03-19 | 2022-12-21 | ChemoCentryx, Inc. | MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR |
| EP4028052A1 (en) * | 2019-09-10 | 2022-07-20 | Novocure GmbH | A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells |
| WO2021127254A1 (en) * | 2019-12-19 | 2021-06-24 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| WO2021132636A1 (ja) * | 2019-12-27 | 2021-07-01 | 特定非営利活動法人Ｎｏｒｔｈ Ｅａｓｔ Ｊａｐａｎ Ｓｔｕｄｙ Ｇｒｏｕｐ | がん治療方法及び医薬 |
| CN115697374A (zh) * | 2020-05-12 | 2023-02-03 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022032312A1 (en) * | 2020-08-07 | 2022-02-10 | Northwestern University | Methods of treating malignant glioblastoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2927240A1 (en) * | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| ES2592216T3 (es) * | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| RU2402360C1 (ru) * | 2009-07-08 | 2010-10-27 | Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) | Способ лечения злокачественной глиомы головного мозга |
| CN102178676B (zh) * | 2011-04-29 | 2012-07-25 | 山东大学 | 一种治疗脑胶质瘤的药物组合物 |
| EP2723381A4 (en) * | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
-
2015
- 2015-12-16 JP JP2017532140A patent/JP2018500332A/ja active Pending
- 2015-12-16 CN CN201580069022.6A patent/CN106999590A/zh active Pending
- 2015-12-16 BR BR112017010101A patent/BR112017010101A2/pt not_active Application Discontinuation
- 2015-12-16 RU RU2017125052A patent/RU2726996C1/ru active
- 2015-12-16 WO PCT/US2015/066177 patent/WO2016100561A2/en not_active Ceased
- 2015-12-16 US US15/536,785 patent/US20180133313A1/en not_active Abandoned
- 2015-12-16 EP EP15871017.8A patent/EP3233123A4/en active Pending
- 2015-12-16 CA CA2969338A patent/CA2969338A1/en not_active Abandoned
- 2015-12-16 MX MX2017007390A patent/MX2017007390A/es unknown
-
2020
- 2020-07-20 US US16/933,547 patent/US20210000953A1/en not_active Abandoned
-
2021
- 2021-08-12 JP JP2021131637A patent/JP2021181482A/ja active Pending
-
2023
- 2023-12-06 US US18/531,312 patent/US20240238416A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500332A5 (enExample) | ||
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| JP2019503387A5 (enExample) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP2019517512A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2018522887A5 (enExample) | ||
| JP2017507155A5 (enExample) | ||
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| US10842743B2 (en) | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents | |
| KR102463617B1 (ko) | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2018516969A5 (enExample) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018514550A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| JP2014533279A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| HRP20181646T2 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| JP2019517505A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2019522657A5 (enExample) |